Back to Resource Center

Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis

Women in sub-Saharan Africa (SSA) experience the world’s highest rates of both HIV infection and unintended pregnancy. The Dual Prevention Pill (DPP) is a novel multipurpose prevention technology (MPT) that co-formulates HIV pre-exposure prophylaxis (PrEP) and combined hormonal oral contraception into a single daily pill. As a dual indication product, the DPP may be preferred by women facing these overlapping health risks. However, most SSA countries face severe healthcare resource constraints. Research is needed to assess whether, in what populations, and in what use cases the DPP would be cost-effective. The DPP has the potential to be cost-effective and cost-saving in populations at substantial HIV risk. Outcomes are sensitive to adherence, implying that effective counseling and decision-making tools for users considering the DPP will be essential. More research is needed to understand real-life adherence patterns and ensure health benefits achieved from contraception alone are not lost.

May 2023

Click for full info +

Full Info:


Resource Type:

Database
Journal Article
Journal Article
MPT Articles
MPT Article
Resource

Citation:

Women in sub-Saharan Africa (SSA) experience the world’s highest rates of both HIV infection and unintended pregnancy. The Dual Prevention Pill (DPP) is a novel multipurpose prevention technology (MPT) that co-formulates HIV pre-exposure prophylaxis (PrEP) and combined hormonal oral contraception into a single daily pill. As a dual indication product, the DPP may be preferred by women facing these overlapping health risks. However, most SSA countries face severe healthcare resource constraints. Research is needed to assess whether, in what populations, and in what use cases the DPP would be cost-effective. The DPP has the potential to be cost-effective and cost-saving in populations at substantial HIV risk. Outcomes are sensitive to adherence, implying that effective counseling and decision-making tools for users considering the DPP will be essential. More research is needed to understand real-life adherence patterns and ensure health benefits achieved from contraception alone are not lost.

View Journal Article

Authors: Milali, M.P., Resar, D., Kaftan, D., Campbell, J., Olowu, A., Edwards, D., Platais, I., Kim, H.Y., Jenkins, S. and Bershteyn, A.

Health Risks(s):

  • HIV
  • Unintended Pregnancy

Product type(s):

  • Contraceptives
  • HIVinhibitor
  • Hormonal
  • MPTs

Topic(s):

  • MPTs
  • Product Introduction
  • Social

Region(s)

  • Africa

Back to Resource Center